BioTime, Inc. company was founded in 1990 and is headquartered in Alameda, California. BioTime, Inc. is a biomedical organization engaged in the development of synthetic plasma expanders and blood volume substitute solutions for use in surgery, trauma care, organ transplant procedures, and other areas of medicine. The Company’s operating revenues have been generated primarily from licensing fees related to the sale of its plasma volume expander products, primarily Hextend. The company began to make its first stem cell research products available during the year ended December 31, 2008, but it had not yet generated significant revenues in that business segment.

Servier is an independent, French pharmaceutical company which manufactures and sells drugs to combat cardiovascular diseases, such as coronary artery disease, hypertension, and stroke. Cardiovascular drugs account for about two-thirds of the company's annual revenues. It also produces medicines to treat diabetes, venous disease, and cancer. Annually, more than 700 million boxes of drugs are produced by Servier. Its pharmaceutics can be found in 140 countries; 80% of its sales are generated internationally.

Human Genome Sciences, Inc. was founded in 1992 and is headquartered in Rockville, Maryland. Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. The company's clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer. It focuses on the commercialization of Albuferon (albinterferon alfa-2b) for hepatitis C and LymphoStat-B (belimumab) for lupus. The company has completed Phase III development trials for Albuferon and is conducting two Phase III clinical trials of LymphoStat-B. It also delivers doses of ABthrax (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax. In addition, the company has various drugs in the earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. Further, Human Genome Sciences, Inc., through a strategic collaboration agreement with GlaxoSmithKline, has substantial financial rights to certain products in the GlaxoSmithKline clinical pipeline, including darapladib that is in Phase III development as a treatment for coronary heart disease; and Syncria (albiglutide), which is in Phase III development as a treatment for type 2 diabetes. Additionally, it has a strategic commercial collaboration agreement with Novartis International Pharmaceutical, Ltd. for the co-development and commercialization of Albuferon; and a strategic licensing and collaboration agreement with Aegera Therapeutics, Inc. to develop and commercialize HGS1029 and other small-molecule inhibitors of IAP (inhibitor of apoptosis) proteins in oncology.

Nature's Way Holding Company manufactures and markets nutritional supplements and other OTC products which are sold with the Enzymatic Therapy, Nature's Way, and Remifemin labels through natural foods retailers and mass market retailers in the US. Its products are aimed to alleviate everything from sleeplessness to hot flashes and are distributed throughout the US and to more than 40 other countries. Its Integrative Therapeutics and Vitaline brands are sold through healthcare practitioners' offices. The company is a unit of German firm Dr. Willmar Schwabe Pharmaceuticals.

Marligen Biosciences is where researchers go again and again for testing products and services. The company makes nucleic acid purification systems, genetic analysis assays, and other genomics research supplies. Its nucleic acid purification systems include rapid plasma purification systems which are used for isolation DNA so it can mapped, cloned, amplified, labeled, and sequenced. Its genetic analysis assays are sold under the Signet brand name and can screen for certain classes of DNA or be tailored to the researchers needs. Marlingen was acquired by another genetic services provider, OriGene, in 2009.

Bellus Health scientists are putting their gray matter to work to find therapies for incurable conditions. Formerly known as Neurochem, Bellus Health's lead candidate is a potential treatment for Amyloid A amyloidosis, an often fatal condition associated with inflammatory disease and kidney dysfunction. Bellus has licensed the late-stage compound to Centocor, which plans to market it under the name Kiacta. Bellus is also evaluating a potential treatment for type 2 diabetes in clinical trials and has discovery programs in the areas of Alzheimer's disease, diabetes, and metabolic syndrome. Its OVOS Natural Health business is touting homotaurine as a nutritional supplement to improve memory and cognition.

Lorus Therapeutics isn't talking nonsense, they're talking antisense. The biotechnology firm is developing cancer drugs using antisense technology, which prevents cells from producing disease-causing proteins and may cause fewer side effects than traditional chemotherapies. It is testing its lead candidate in this area, LOR-2040, as a treatment for various blood cancers and solid tumors. Lorus is working in other areas of cancer research as well, developing some traditional therapies, as well as immunotherapies, which stimulate the body's immune system to fight cancer. The company licensed its Virulizin immunotherapy, a potential treatment for pancreatic cancer, to a subsidiary of Zoticon Bioventures in 2008.

Pfizer Limited company is the top provider of medicines to the UK's National Health Service, offering many of its parent company's products to treat conditions including cardiovascular ailments and cancers. It also provides animal health products. Pfizer Limited conducts research and development activities, focusing on medications in the areas of allergy, respiratory, urinary, metabolic, and gastrointestinal ailments, as well as vaccines, anti-retrovirals, and pain treatments.

Proteome Sciences plc is a United Kingdom-based company. The Company is principally engaged in biomarker research and development primarily in the field of applied proteomics, using techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. Through its ProteoSHOP toolkit, Proteome Sciences provides proteomics solutions, including traditional two dimensional gel-based electrophoresis (2DE) and gel-free protein sequence tag technologies (PST, qPST& TMT), to pharma, biotechnology and diagnostic companies. The Company has research facilities in London, the United Kingdom and Frankfurt, Germany. Its subsidiaries include Proteome Sciences R&D Verwaltungs GmbH, Proteome Sciences R&D GmbH & Co. KG, Xzillion GmbH & Co. KG, Proteome Sciences, Inc., Veri-Q Inc., Phenomics Limited and Electrophoretics Limited.

Myriad Genetics, Inc. company was founded in 1991 and is headquartered in Salt Lake City, Utah. Myriad Genetics, Inc., a healthcare company, focuses on the development and marketing of novel molecular diagnostic products. It commercializes predictive medicine, personalized medicine, and prognostic medicine products. The company markets BRACAnalys for assessing a woman's risk for breast and ovarian cancer; COLARIS molecular for assessing a person's risk of developing colorectal cancer or uterine cancer; COLARIS AP, a molecular diagnostic product for colon cancer that detects mutations in the APC and MYH genes; and MELARIS, which assesses a persons risk of developing melanoma. It also offers OnDose, a personalized medicine product to measure a patient's exposure to 5-FU chemotherapy; PREZEON that assesses loss of PTEN function in cancer patients; and TheraGuide 5-FU assesses a person's risk of developing a toxic reaction to 5-FU-based chemotherapy.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.